Sentences with phrase «ipilimumab at»

We gave ipilimumab at 1 mg / kg and nivolumab at 3 mg / kg, and that regimen was much better tolerated.

And of those 20 patients, more than half couldn't finish the 12 - week induction regimen because we used the high dose of ipilimumab at 3 mg / kg, whereas nivolumab was given at 1 mg / kg.

Not exact matches

At a median follow - up of 2.74 years, the median recurrence - free survival was 26.1 months (95 % confidence interval (CI) 19.3 — 39.3) in the Ipilimumab group and 17.1 months (95 % CI 13.4 — 21.6) in the placebo group (hazard ratio 0.75; 95 % CI 0.64 — 0.90; p = 0.0013).

In absolute terms, the overall survival rate at five years was 11 % higher in the ipilimumab arm (65 %) than in the placebo arm (54 %).

Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time at the ESMO 2016 Congress in Copenhagen.

Our intention with this study was to assess Ipilimumab as an adjuvant treatment for patients with completely resected stage III melanoma at high risk of recurrence.

The results of the trial, which compared a combination of checkpoint inhibitors ipilimumab and nivolumab against ipilimumab alone in previously untreated patients, were presented today at the 2015 Annual Meeting of the American Association for Cancer Research and have been simultaneously published in the New England Journal of Medicine.

The first such drug, called ipilimumab (Yervoy), developed out of Allison's basic science research, showed much lower response rates against advanced melanoma than those obtained with targeted drugs, but long - term follow - up found that 22 percent of those treated with Yervoy survived at least four years, unprecedented results for the disease.

Mathias Chamaillard at the University of Lille, France, and his colleagues discovered that the skin cancer drug ipilimumab isn't as effective at treating cancer in mice born without bacteria in their gut, compared with mice with normal bacteria.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

Moffitt Cancer Center researchers participated in an international phase 3 study that demonstrated that a drug called ipilimumab improves the relapse - free survival of advanced stage melanoma patients rendered free of disease surgically but at high risk for relapse.

They are investigating other bacteria that could influence other immune therapies, such at the CTLA - 4 pathway, exploited by ipilimumab.

The trial looked at 60 patients treated with investigator's choice of nivolumab, pembrolizumab, or ipilimumab plus indoximod.

Our multicenter retrospective analysis evaluated 33 patients with advanced mucosal melanoma who received ipilimumab, the majority of whom had been pretreated with at least one prior line of therapy.

They are investigating bacteria that could influence other immune therapies, such at the CTLA - 4 pathway, exploited by ipilimumab.

[76] An evaluation of 71 patients with metastatic mucosal melanoma treated with ipilimumab through an expanded access program in Italy reported a response rate of 12 % and a disease control rate of 36 % at a median follow - up time of 21.8 months.

A University of California at Los Angeles (UCLA) study headed by Antoni Ribas, M.D., Ph.D., is a first - in - human phase I clinical trial combining adoptive cell transfer of a T cell receptor engineered to recognize NY - ESO - 1 along with Yervoy ® (ipilimumab, anti-CTLA-4).

Dr. Wolchok has been at the forefront of cancer immunotherapy and is renowned for leading the clinical trials that led to the first FDA - approved checkpoint inhibitor immunotherapy, the anti-CTLA-4 antibody ipilimumab.

At the most promising dose level (nivolumab 1 mg / kg and ipilimumab 3 mg / kg), the 2 - year survival rate was even more impressive — 88 %.

Long - term follow - up of patients who received ipilimumab showed that a large percentage were still alive at the two - and five - year mark.

At 18 months, the relapse - free survival rate for nivolumab was 66 percent, compared with 53 percent for ipilimumab.

This may be best addressed by a tailored development paradigm,» says CIC Executive Committee member and a lead investigator in the ipilimumab clinical development program Jedd D. Wolchok, M.D., Ph.D., who is director of the Immunotherapy Clinical Trials Program at Memorial Sloan - Kettering Cancer Center in New York City.

A recent study, she said, looked at adjuvant nivolumab vs ipilimumab in patients with resected stage III or IV melanoma.

At a very early follow - up, nivolumab treatment resulted in a statistically significant 12 - month relapse - free survival rate compared with ipilimumab.

The Melanoma Intra-Tumoral CAVATAK and Ipilimumab (MITCI) study [26] of CVA21 in combination with systemic administration of ipilimumab in patients with unresectable melanoma is being conducted at threeIpilimumab (MITCI) study [26] of CVA21 in combination with systemic administration of ipilimumab in patients with unresectable melanoma is being conducted at threeipilimumab in patients with unresectable melanoma is being conducted at three US sites.